Hepatitis C virus genotypes and hepatic fibrosis regulate 24-h decline of serum hepatitis
C virus RNA during interferon therapy in patients with chronic hepatitis C.
Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis
B surface antigen levels.
Is there a meaningful serum hepatitis
B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection?
The incubation period for onset of biochemical disease after experimental inoculation of PCR-positive tetanus antitoxin to the 2 horses was longer (82 and 94 days) than most reported clinical cases of equine serum hepatitis
. Clinical cases typically occur 6-10 weeks after blood product inoculation, but cases have been reported as long as 14 weeks after blood product administration (5,7).
Cao et al., "Negative correlation of serum hepatitis
B surface antigen and hepatitis B e antigen levels with the severity of liver inflammation in treatment-naive patients with chronic hepatitis B virus infection," Chinese Medical Journal, vol.
Among the non-drinkers studied, 46 percent had an early virologic response; 26 percent had no detectable serum hepatitis
C virus (HCV) ribonucleic acid at week 20; 22 percent had no detectable serum at week 48; and 11 percent had a sustained virologic response.
B virus DNA levels and liver histology in inactive HBsAg carriers.
Sex differences in relation to serum hepatitis
B e antigen and alanine aminotransferase levels among asymptomatic hepatitis B surface antigen carriers.
Clinical Evaluation of the Automated COBAS Amplicor HCV monitor test Version 2.0 for Quantifying Serum Hepatitis
C Virus RNA and Comparison to the Quantiplex HCV Version 2.0 Test.
However, serum hepatitis
B DNA is costly and not routinely performed in South Africa, especially in the public sector.
Patients were included in the study if they were positive for serum hepatitis
B surface antigen or C antibodies and had persistently elevated serum aminotransferase concentrations greater than 1.5 times the upper limit of the reference range for at least six months.
Risk of hepatocellular carcinoma across biological gradient of serum hepatitis
B virus DNA level.
The seriousness of serum hepatitis
may be accentuated in a uremic patient whose general condition is poor and whose resistance to infection is low.
B virus DNA was reduced to a significantly greater degree in all patients who received telbivudine than in those who received lamivudine, regardless of their HBeAg status.
(SH) antigen amongst patients with liver diseases and voluntary blood donors-A prospective study.